Toward the development of a one-dose classical swine fever subunit vaccine: antigen titration, immunity onset, and duration of immunity
10.4142/jvs.2018.19.3.393
- Author:
Rachel F MADERA
1
;
Lihua WANG
;
Wenjie GONG
;
Yulia BURAKOVA
;
Sterling BUIST
;
Jerome NIETFELD
;
Jamie HENNINGSON
;
Ada G CINO-OZUNA
;
Changchun TU
;
Jishu SHI
Author Information
1. Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA. jshi@ksu.edu
- Publication Type:Original Article
- Keywords:
adjuvants;
classical swine virus;
subunit;
vaccines
- MeSH:
Animals;
Classical Swine Fever;
Glycoproteins;
Swine;
Vaccines
- From:Journal of Veterinary Science
2018;19(3):393-405
- CountryRepublic of Korea
- Language:English
-
Abstract:
Highly contagious classical swine fever (CSF) remains a major trade and health problem in the pig industry, resulting in large economic losses worldwide. In CSF-endemic countries, attenuated CSF virus (CSFV) vaccines have been routinely used to control the disease. However, eradication of CSFV in a geographical area would require permanent reduction to zero presence of the virus. It is therefore of paramount importance to develop a safe, potent, and non-infectious CSF vaccine. We have previously reported on a cost-effective CSF E2 subunit vaccine, KNB-E2, which can protect against CSF symptoms in a single dose containing 75 µg of recombinant CSFV glycoprotein E2. In this study, we report on a series of animal studies undertaken to elucidate further the efficacy of KNB-E2. We found that pigs vaccinated with a single KNB-E2 dose containing 25 µg of recombinant CSFV glycoprotein E2 were protected from clinical symptoms of CSF. In addition, KNB-E2-mediated reduction of CSF symptoms was observed at two weeks post-vaccination and the vaccinated pigs continued to exhibit reduced CSF clinical signs when virus challenged at two months and four months post-vaccination. These results suggest that KNB-E2 effectively reduces CSF clinical signs, indicating the potential of this vaccine for safely minimizing CSF-related losses.
